Pre-made Nivolumab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Nivolumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction (GEJ) cancer. It is used by slow injection into a vein.
| Products Name (INN Index) | Pre-Made Nivolumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody |
|---|---|
| INN Name | Nivolumab |
| Target | PDCD1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 5ggq:HL/5wt9:HL/5ggr:HL:AB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Aduro BioTech,AIO Studien gGmbH,Australian and New Zealand Urogenital and Prostate Cancer Group,Barbara Ann Karmanos Cancer Institute,Bavarian Nordic,Big Ten Cancer Research Consortium,Bristol-Myers |
| Conditions Approved | Colorectal cancer,Gastric cancer,Head and neck cancer,Hodgkin's disease,Malignant melanoma,Non-small cell lung cancer,Renal cell carcinoma,Urogenital cancer,Liver cancer,Mesothelioma,Small cell lung |
| Conditions Active | Bladder cancer,Fallopian tube cancer,Glioblastoma,Multiple myeloma,Oesophageal cancer,Ovarian cancer,Peritoneal cancer,Non-Hodgkin's lymphoma,Acute myeloid leukaemia,Adrenocortical carcinoma,Biliary |
| Conditions Discontinued | Chronic myeloid leukaemia,Hepatitis C,Sepsis |
| Development Tech | Medarex UltiMAb Mouse |
| Previous Name | NA |
| Gm Offical Target Name | PDCD1 |
| Package |
